Literature DB >> 21898480

Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors.

Marianna Hösel1, Mathias Broxtermann, Hanna Janicki, Knud Esser, Silke Arzberger, Pia Hartmann, Sonja Gillen, Jörg Kleeff, Dirk Stabenow, Margarete Odenthal, Percy Knolle, Michael Hallek, Ulrike Protzer, Hildegard Büning.   

Abstract

UNLABELLED: Adeno-associated viral vectors (rAAV) are frequently used in gene therapy trials. Although rAAV vectors are of low immunogenicity, humoral as well as T cell responses may be induced. While the former limits vector reapplication, the expansion of cytotoxic T cells correlates with liver inflammation and loss of transduced hepatocytes. Because adaptive immune responses are a consequence of recognition by the innate immune system, we aimed to characterize cell autonomous immune responses elicited by rAAV in primary human hepatocytes and nonparenchymal liver cells. Surprisingly, Kupffer cells, but also liver sinusoidal endothelial cells, mounted responses to rAAV, whereas neither rAAV2 nor rAAV8 were recognized by hepatocytes. Viral capsids were sensed at the cell surface as pathogen-associated molecular patterns by Toll-like receptor 2. In contrast to the Toll-like receptor 9-mediated recognition observed in plasmacytoid dendritic cells, immune recognition of rAAV in primary human liver cells did not induce a type I interferon response, but up-regulated inflammatory cytokines through activation of nuclear factor κB.
CONCLUSION: Using primary human liver cells, we identified a novel mechanism of rAAV recognition in the liver, demonstrating that alternative means of sensing rAAV particles have evolved. Minimizing this recognition will be key to improving rAAV-mediated gene transfer and reducing side effects in clinical trials due to immune responses against rAAV.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21898480     DOI: 10.1002/hep.24625

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  62 in total

1.  Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

Authors:  Ashley T Martino; Etiena Basner-Tschakarjan; David M Markusic; Jonathan D Finn; Christian Hinderer; Shangzhen Zhou; David A Ostrov; Arun Srivastava; Hildegund C J Ertl; Cox Terhorst; Katherine A High; Federico Mingozzi; Roland W Herzog
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

2.  Filling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy.

Authors:  Suriyasri Subramanian; Anna C Maurer; Carol M Bator; Alexander M Makhov; James F Conway; Kevin B Turner; James H Marden; Luk H Vandenberghe; Susan L Hafenstein
Journal:  Hum Gene Ther       Date:  2019-11-14       Impact factor: 5.695

3.  Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Annu Rev Virol       Date:  2019-07-05       Impact factor: 10.431

4.  Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.

Authors:  Wenwei Shao; Lauriel F Earley; Zheng Chai; Xiaojing Chen; Junjiang Sun; Ting He; Meng Deng; Matthew L Hirsch; Jenny Ting; R Jude Samulski; Chengwen Li
Journal:  JCI Insight       Date:  2018-06-21

5.  Microbiome-Immune Interactions and Liver Disease.

Authors:  James H Tabibian; Cyril Varghese; Steven P O'Hara; Nicholas F LaRusso
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-05-07

Review 6.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 7.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

8.  IL-24 sensitizes tumor cells to TLR3-mediated apoptosis.

Authors:  R Weiss; M Sachet; J Zinngrebe; T Aschacher; M Krainer; B Hegedus; H Walczak; M Bergmann
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

9.  Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Authors:  Masataka Suzuki; Terry K Bertin; Geoffrey L Rogers; Racel G Cela; Irene Zolotukhin; Donna J Palmer; Philip Ng; Roland W Herzog; Brendan Lee
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

Review 10.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.